New Study on Ophthalmology Therapeutics Market

The report “Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity″ by  GBI Research is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Ophthalmology therapeutics’ market research reports has a new addition of “Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity” on RnRMarketResearch.com “Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity”, which provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

Request a sample copy of this report by GBI Research@ http://www.rnrmarketresearch.com/contacts/request-sample?rname=127327 .

Scope

• Disease overview and treatment usage patterns
• Market size and forecast for glaucoma and DES in APAC market from 2012 to 2019
• Major marketed products for the indications types covered
• In-depth pipeline analysis for glaucoma and DES
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements in the ophthalmology market

Complete report is available @ http://www.rnrmarketresearch.com/ophthalmology-therapeutics-market-in-asia-pacific-to-2019-high-unmet-need-and-moderate-short-term-prospects-focus-attention-on-early-stage-activity-market-report.html . Read more on “Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity” report below.

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

For further information on “Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity” report OR for any other business research / market intelligence need on the ‘Ophthalmology therapeutics’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

Mania, Nocturia & Osteopenia Therapeutics Market Pipeline Review H1 2013

RnRMarketResearch.com adds “Osteopenia – Pipeline Review, H1 2013” “Mania – Pipeline Review, H1 2013” and “Nocturia – Pipeline Review, H1 2013” on its database.

‘Mania, Nocturia & Osteopenia – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mania, Nocturia & Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mania, Nocturia & Osteopenia. Mania, Nocturia & Osteopenia – Pipeline Review, Half Year is built using data and information.

Complete Report Copy of Osteopenia – Pipeline Review, H1 2013 @ http://www.rnrmarketresearch.com/osteopenia-pipeline-review-h1-2013-market-report.html. Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=106661.

Scope

- A snapshot of the global therapeutic scenario for Mania, Nocturia & Osteopenia.
- A review of the Mania, Nocturia & Osteopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mania, Nocturia & Osteopenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Complete Report Copy of Mania – Pipeline Review, H1 2013 @ http://www.rnrmarketresearch.com/mania-pipeline-review-h1-2013-market-report.html. Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=106654.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mania, Nocturia & Osteopenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mania, Nocturia & Osteopenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Complete Report Copy of Nocturia – Pipeline Review, H1 2013 @ http://www.rnrmarketresearch.com/nocturia-pipeline-review-h1-2013-market-report.html. Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=106659.

Table of Content

Companies Involved in Osteopenia Therapeutics Development
Amgen Inc.
Novartis AG
Pfizer Inc.

Companies Involved in Mania Therapeutics Development
Gedeon Richter Plc.

Newron Pharmaceuticals S.p.A.
Reviva Pharmaceuticals Inc.

Companies Involved in Nocturia Therapeutics Development

Allergan, Inc.

Urigen Pharmaceuticals, Inc.

Vantia Therapeutics

Drais Pharmaceuticals, Inc.

Explore More Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals

Myeloproliferative Disorders – Pipeline Review, H1 2013

‘Myeloproliferative Disorders – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Myeloproliferative Disorders – Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Complete Report Copy @ http://www.rnrmarketresearch.com/myeloproliferative-disorders-pipeline-review-h1-2013-market-report.html.

Scope

- A snapshot of the global therapeutic scenario for Myeloproliferative Disorders.
- A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=106615.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myeloproliferative Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myeloproliferative Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Global Markets Direct Report Coverage 9
Myeloproliferative Disorders Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Myeloproliferative Disorders 11
Myeloproliferative Disorders Therapeutics under Development by Companies 13
Myeloproliferative Disorders Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Myeloproliferative Disorders Therapeutics - Products under Development by Companies 20
Myeloproliferative Disorders Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Myeloproliferative Disorders Therapeutics Development 23
Bristol-Myers Squibb Company 23
Sanofi-Aventis 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Genentech, Inc. 27
Gilead Sciences, Inc. 28
Merck & Co., Inc. 29
Nanotherapeutics, Inc. 30
Novartis AG 31

Explore More Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals

Attention-Deficit/Hyperactivity Disorder (ADHD) Therapeutics Market 2018 at RnRMarketResearch.com

The impending publication of the fifth edition of the American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-V) may affect diagnosis rates of conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD), both in the US and worldwide.
European countries are increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more and more diagnoses of ADHD. This may eventually result in a rise in ADHD diagnoses even further afield.

Although Europe trails behind the US in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over 2012-2018, beating the US CAGR of 6% during the same future period. European markets have not yet neared the saturation point that ADHD therapeutics are facing in the US, and there is an optimistic view for ambitious growth in this region. The ADHD therapeutics market across France, Germany, Italy, Spain and the UK is predicted to reach approximately $182m in 2018.

Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=99800

This report “ADHD Therapeutics Market to 2018 – New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment” provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

Scope:

• Current and future treatment and diagnosis trends for ADHD
• Market forecasts for ADHD across seven major markets
• Analysis of the developmental pipelines for ADHD
• Information on recent industry deals

Reasons to Buy:

• Understand how the ADHD market has developed and is continuing to develop within the featured markets
• Predict which products are likely to be most successful in the future
• Gain an understanding of the possible market available for specific products

Get a copy of this report @ http://www.rnrmarketresearch.com/adhd-therapeutics-market-to-2018-market-report.html